A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg

Current Medical Research and Opinion

Volumn 24, Issue 3, 2008, Pages 695-705

  Abelson, Abby ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bisphosphonates; Metabolic bone diseases; Paget's disease; Risedronate; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACUPUNCTURE; ARTHRALGIA; BACKACHE; BONE NECROSIS; BONE PAIN; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC IMAGING; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; FLU LIKE SYNDROME; FRACTURE; HEADACHE; HEARING LOSS; HUMAN; HYDROTHERAPY; HYPOCALCEMIA; INJECTION SITE REACTION; JAW DISEASE; LIMB PAIN; MYALGIA; NAUSEA; NERVE STIMULATION; NEUROLOGIC DISEASE; PAGET BONE DISEASE; PREVALENCE; RADIODIAGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RIGOR; SINGLE DRUG DOSE; SKELETON MALFORMATION; STANDARD; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION; TREATMENT RESPONSE;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE PROGRESSION; ETIDRONIC ACID; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEITIS DEFORMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 41149151809     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X260899     Document Type: Review

References (60)

1. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest 2005;115:200-8
2. Altman RD. Paget's disease of bone. In: Coe FL, Favus MJ, editors. Disorders of bone and mineral metabolism, 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2002. p. 985-1020
3. Siris ES, Roodman GD. Paget's disease of bone. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th ed. Washington (DC): American Society for Bone and Mineral Research; 2003. p. 495-506
4. Langston AL, Ralston SH. Management of Paget's disease of bone. Rheumatology 2004;43:955-9
5. Selby PL, Davie MWJ, Ralston SH, Stone MD. Guidelines on the management of Paget's disease of bone. Bone 2002;31:366-73
6. Ankrom MA, Shapiro JR. Paget's disease of bone (osteitis deformans). J Am Geriatr Soc 1998;46:1025-33
7. Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 2001;16:1379-87
8. Cooper C, Schafheutle K, Dennison E, et al. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999;14:192-7
9. Cundy HR, Gamble G, Wattie D, et al. Paget's disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 2004;75:358-64
10. Poór G, Donáth J, Fornet B, Cooper C. Epidemiology of Paget's disease in Europe: the prevalence is decreasing. J Bone Miner Res 2006;21:1545-9
11. Mirón-Canelo JA, Del Pino-Montes J, Vicente-Arroyo M, Sálenz-González MC; the Paget's disease of the bone group of Salamanca. Epidemiological study of Paget's disease of bone in a zone of the province of Salamanca (Spain). Eur J Epidemiol 1997;13:801-5
12. Leach RJ, Singer FR, Cody JD, Roodman GD. Variable disease severity associated with a Paget's disease predisposition gene. J Bone Miner Res 1999;14:17-20
13. Cody JD, Singer FR, Roodman GD, et al. Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 1997;61:1117-22
14. Haslam SI, Van Hul W, Morales-Piga A, et al. Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 1998;13:911-7
15. Cavey JR, Ralston SH, Hocking LJ, et al. Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 2005;20:619-24
16. Cavey JR, Ralston SH, Sheppard PW, et al. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif Tissue Int 2006;78:271-7
17. Hocking LJ, Lucas GJA, Daroszewska A, et al. Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 2004;19:1122-7
18. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002;70:1582-8
19. Rebel A, Malkani K, Basle M, et al. Ultrastructural characteristics of osteoclasts in Paget's disease. Rev Rhum Mal Osteoartic 1974;41:767-71
20. Mii Y, Miyauchi Y, Honoki K, et al. Electron microscopic evidence of a viral nature for osteoclast inclusions in Paget's disease of bone. Virchows Arch 1994;424:99-104
21. Ralston SH, Helfrich MH. Are paramyxoviruses involved in Paget's disease? A negative view. Bone 1999;24(Suppl):17S-18S
22. Hoyland JA, Freemont AJ, Sharpe PT. Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease. J Bone Miner Res 1994;9:75-80
23. Neale SD, Schulze E, Smith R, Athanasou NA. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease. QJM 2002;95:233-40
24. Roodman GD, Kurihara N, Ohsaki Y, et al. Interleukin 6: a potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992;89:46-52
25. Kanis JA. Clinical features and complications. In: Kanis JA, editor. Pathophysiology and treatment of Paget's disease of bone. London (UK): Martin Dunitz; 1998. p. 110-38
26. Briesacher BA, Orwig D, Seton M, et al. Medical care costs of Paget's disease of bone in a privately insured population. Bone 2006;38:731-7
27. Herzberg L, Bayliss E. Spinal-cord syndrome due to non-compressive Paget's disease of bone: a spinal-artery steal phenomenon reversible with calcitonin. Lancet 1980;2:13-5
28. Eisman JA, Martin TJ. Osteolytic Paget's disease: recognition and risks of biopsy. J Bone Joint Surg Am 1986;68:112-7
29. Delmas PD, Meunier PJ. The management of Paget's disease of bone. New Engl J Med 1997;336:558-66
30. Eastell R. Biochemical markers of bone turnover in Paget's disease of bone. Bone 1999;24(Suppl):49S-50S
31. Ralston SH, Boyce BF, Cowan RA, et al. The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease - a double-blind randomized clinical study. J Bone Miner Res 1987;2:5-12
32. Reginster JY, Colson F, Morlock G, et al. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone: a double-blind, multiple-dosage, placebo-controlled study. Arthritis Rheum 1992;35:967-74
33. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996;101:341-8
34. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. New Engl J Med 2005;353:898-908
35. Kurtzweil P. Help for people with Paget's disease. FDA Consumer. 1996;30. Available at http://www.fda.gov/fdac/features/896_pag.html [accessed February 12, 2007]
36. Meunier PJ, Vignot E. Therapeutic strategy in Paget's disease of bone. Bone 1995;17(Suppl):489S-491S
37. Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget's disease of bone. J Bone Miner Res 1993;8:1467-73
38. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42
39. Frith JC, Mönkkönen J, Auriola S, et al. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001;44:2201-10
40. Actonel® [prescribing information]. Cincinnati (OH): Procter & Gamble Pharmaceuticals, Inc.: May 2007
41. Didronel® [prescribing information]. Cincinnati (OH): Procter & Gamble Pharmaceuticals, Inc.: May 2005
42. Fosamax® [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc.: December 2006
43. Skelid® [prescribing information]. Bridgewater (NJ): Sanofi-Aventis: April 2006
44. Aredia® [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation: February 2007
45. Recladt® [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; April 2007
46. Fogelman I, Smith L, Mazess R, et al. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) 1986;24:57-62
47. Roux C, Dougados M. Treatment of patients with Paget's disease of bone. Drugs 1999;58:823-30
48. Canfield R, Rosner W, Skinner J, et al. Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 1977;44:96-106
49. Fraser WD, Stamp TC, Creek RA, et al. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J 1997;73:496-502
50. Miller PD, Brown JP, Siris ES, et al.; for the Paget's Risedronate/Etidronate Study Group. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999;106:513-20
51. Rendina D, Mossetti G, Viceconti R, et al. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int 2004;75:189-96
52. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995;38:851-8
53. Russell RG, Smith R, Preston C, et al. Diphosphonates in Paget's disease. Lancet 1974;1:894-8
54. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 1998;13:1032-8
55. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27
56. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51
57. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002;55:210-24
58. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142-8
59. Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone 2006;39:954-8
60. Black DM, Delmas PD, Eastell R, et al.; for the HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med 2007;356:1809-22